University Hospital Sveti Duh — Clinical Trial Site

23 Registered trials

13 Currently recruiting

Organisation

University Hospital Sveti Duh

Location

Zagreb, Croatia

Identifier

ORG-100023157

Address

Sveti Duh 64, 10000, Croatia

Departments

#7000
#9008:Neurology
1802_Pulmonology department
2107: Cardiology
8008: Neurology
Deaprtment of Neurology
Department for Cardiovascular Diseases
Department of Clinical Pharmacology and Toxicology
Department of Haematology and Coagulation
Department of Nephrology
Department of Nephrology and Dialysis
Department of Orthopaedics and Traumatology
Department Of Physical Medicine and Rehabilitation
Department Of Physical Medicine and Rehabilitation
Endocrinology
IInstitute of cardiovascular diseases
Neurology clinic
Ophthalmology
Physical Medicine and Rehabilitation

Clinical trials at this site (23)

Search interface

A randomized, double-blind, placebo-controlled multicenter study to evaluate the effect of inclisiran on preventing major adverse cardiovasc… Unknown

2022-502779-40-99 Primary prevention of atherosclerotic cardiovascular di 5
PODOMOUNT-Basket, a study to test whether BI 764198 helps adults and adolescents with different types of kidney disease Recruiting

2025-523425-17-00 Proteinuric kidney diseases 4 2026-06-03
A study to find out if BI 764198 helps adults and adolescents with a kidney condition called focal segmental glomerulosclerosis (FSGS) Recruiting

2025-522191-86-00 Focal segmental glomerulosclerosis 5 2026-04-02
A study to find how well Dazodalibep works and how safe it is in participants with Sjôgren`s Syndrome Recruiting

2023-503904-10-00 Sjögren’s Syndrome With Moderate-to-severe Systemic Dis 5 2024-06-07
A clinical trial to find out how well LOU064 (remibrutinib) works and how safe it is for people with secondary progressive multiple sclerosi… Recruiting

2025-521546-23-00 Secondary progressive multiple sclerosis 5 2026-04-21
Study to Assess the Injection Burden, Safety, Efficacy, and Long-Term Preservation of Visual Acuity of Surabgene Lomparvovec (ABBV-RGX-314) … Recruiting

2024-512298-28-00 Neovascular age-related macular degeneration 11 2025-12-18
Study to Evaluate Plozasiran in Adults with Severe Hypertriglyceridemia at high risk of Acute Pancreatitis (SHASTA-5 Study) Recruiting

2024-518206-40-00 Severe hypertriglyceridemia (SHTG) 5 2025-11-03
A Study to Evaluate Finerenone on Clinical Efficacy and Safety in Patients with Heart Failure Who Are Intolerant or Not Eligible for Treatme… Recruiting

2023-508875-35-00 Heart condition 5 2025-09-01
Randomized, controlled, multi-center clinical trial for the treatment of osteoarthritis behind the kneecap with tissue engineered nasal cart… Recruiting

2024-513683-25-00 Patellofemoral osteoarthritis 4 2025-06-30
A study to find how well Dazodalibep works and how safe it is in participants with Sjôgren`s Syndrome Recruiting

2024-517513-32-00 Sjögren’s Syndrome 5 2025-05-16
A study to determine if BHV-7000 is safe in adults with refractory focal onset epilepsy Recruiting

2023-508813-18-00 Refractory Focal Onset Epilepsy 4 2024-12-18
202301CPC Redefine-HF Recruiting

2023-508581-15-00 Heart condition 5 2024-10-08
A Randomized, Multi-Center, Parallel, Double-Blinded, Placebo-Controlled Clinical Trial to Evaluate Efficacy, Safety, and Pharmacokinetics o… Recruiting

2022-502193-16-00 Chronic lymphocytic leukemia, Multiple Myeloma and Non- 5 2023-11-14
A Phase 3, multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaLuate the effIcacy and safety of abeLacimab… Recruiting

2023-503224-66-00 Atrial Fibrillation 5 2023-10-31
A study to find how well Dazodalibep works and how safe it is in participants with Sjögren’s Syndrome Ended

2023-503923-24-00 Sjögren’s Syndrome With Moderate-toSevere Symptom State 5 2024-07-22
A randomized, double-blind, placebo-controlled multicenter study to evaluate the effect of inclisiran on preventing major adverse cardiovasc… Ended

2022-502779-40-00 Primary prevention of atherosclerotic cardiovascular di 5 2023-09-04
A Phase 3 Placebo-controlled Study of Milvexian after an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack Ended

2022-501176-26-00 Acute Ischemic Stroke and High-Risk Transient Ischemic 5 2023-08-04
Efficacy and safety of remibrutinib compared to teriflunomide in participants with relapsing multiple sclerosis, followed by long term treat… Ended

2023-509345-12-00 Multiple Sclerosis 5 2022-06-22
A research study to find out whether a medicine called inclisiran helps to prevent cardiovascular death, heart attacks or strokes in people … Ended

2024-510735-21-00 Atherosclerotic cardiovascular disease (ASCVD) 5 2021-11-26
Effectiveness and Safety of Sparsentan as treatment for Immunoglobulin A Nephropathy (IgAN) Ended

2023-505495-30-00 Immunoglobulin A Nephropathy (IgAN) 5 2019-02-01
Efficacy, Safety and Tolerability of BHV-7000 in Subjects with Idiopathic Generalized Epilepsy with Generalized Tonic-clonic Seizures – SHIN… Ended

2023-508812-45-00 Idiopathic Generalized Epilepsy with Generalized Tonic- 10 2024-11-11
A Phase 3 study to assess efficacy and safety of oral tebipenem compared to IV imipenem-cilastatin in adults with cUTI/AP Ended

2023-503785-22-00 complicated urinary tract infection (cUTI) or acute pye 5 2024-03-25
A Phase 2a, Randomised, Double-Blind, Placebo-Controlled Study to Assess Efficacy and Safety of Atuliflapon Given Orally Once Daily for Twel… Ended

2023-509243-27-00 Moderate-to-Severe Uncontrolled Asthma 4 2023-04-12